Boehringer Ingelheim and MOLCURE partner to accelerate AI-driven antibody discovery
Boehringer Ingelheim has entered a multi-year research agreement with MOLCURE to develop next-generation antibody therapeutics using MOLCURE's proprietary AI platform, combining machine learning and experimental data to streamline and enhance drug discovery